| 1. |
- Alarcon, Sonia, et al.
(författare)
-
Endocrine, metabolic and apical effects of in utero and lactational exposure to non-dioxin-like 2,2 ',3,4,4 ',5,5 '-heptachlorobiphenyl (PCB 180) : A postnatal follow-up study in rats
- 2021
-
Ingår i: Reproductive Toxicology. - : Elsevier. - 0890-6238 .- 1873-1708. ; 102, s. 109-127
-
Tidskriftsartikel (refereegranskat)abstract
- PCB 180 is a persistent and abundant non-dioxin-like PCB (NDL-PCB). We determined the developmental toxicity profile of ultrapure PCB 180 in developing offspring following in utero and lactational exposure with the focus on endocrine, metabolic and retinoid system alterations. Pregnant rats were given total doses of 0, 10, 30, 100, 300 or 1000 mg PCB 180/kg bw on gestational days 7-10 by oral gavage, and the offspring were sampled on postnatal days (PND) 7, 35 and 84. Decreased serum testosterone and triiodothyronine concentrations on PND 84, altered liver retinoid levels, increased liver weights and induced 7-pentoxyresorufin O-dealkylase (PROD) activity were the sensitive effects used for margin of exposure (MoE) calculations. Liver weights were increased together with induction of the metabolizing enzymes cytochrome P450 (CYP) 2B1, CYP3A1, and CYP1A1. Less sensitive effects included decreased serum estradiol and increased luteinizing hormone levels in females, decreased prostate and seminal vesicle weight and increased pituitary weight in males, increased cortical bone area and thickness of tibial diaphysis in females and decreased cortical bone mineral density in males. Developmental toxicity profiles were partly different in male and female offspring, males being more sensitive to increased liver weight, PROD induction and decreased thyroxine concentrations. MoE assessment indicated that the 95th percentile of current maternal PCB 180 concentrations do not exceed the estimated tolerable human lipid-based PCB 180 concentration. Although PCB 180 is much less potent than dioxin-like compounds, it shares several toxicological targets suggesting a potential for interactions.
|
|
| 2. |
- Sabet, Julia A., 1986-, et al.
(författare)
-
Feasibility and Acceptability of a Healthy Nordic Diet Intervention for the Treatment of Depression: A Randomized Controlled Pilot Trial
- 2021
-
Ingår i: Nutrients. - Basel : MDPI. - 2072-6643. ; 13
-
Tidskriftsartikel (refereegranskat)abstract
- Healthy diet interventions have been shown to improve depressive symptoms, but thereis a need for randomized controlled trials (RCTs) that are double blind and investigate biologicalmechanisms. The primary objectives of this randomized controlled pilot trial were to test thepalatability of the meals and the acceptability of the intervention in preparation for an 8-week RCTin the future, which will investigate whether a healthy Nordic diet improves depressive symptomsin individuals with major depressive disorder, and associated biological mechanisms. Depressed(n = 10) and non-depressed (n = 6) women and men were randomized to receive either a healthyNordic diet (ND) or a control diet (CD) for 8 days. Participants were blinded to their diet allocationand the study hypotheses. Health questionnaires were completed before and after the interventionand, throughout the study, questionnaires assessed participants’ liking for the meals, their sensoryproperties, adherence, and open-ended feedback. In the ND group, 75% of participants consumedonly the provided foods, as instructed, compared to 50% of CD participants. The meals of both diets,on average, received good ratings for liking and sensory properties, though the ND ratings weresomewhat higher. Overall, results were positive and informative, indicating that the planned RCTwill be feasible and well-accepted, with some proposed modifications.
|
|
| 3. |
- Adamson, Carly, et al.
(författare)
-
Efficacy of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Body Mass Index.
- 2021
-
Ingår i: European journal of heart failure. - : Wiley. - 1388-9842 .- 1879-0844. ; 23:10, s. 1662-1672
-
Tidskriftsartikel (refereegranskat)abstract
- AIMS: In heart failure with reduced ejection fraction (HFrEF), there is an ’obesity paradox’, where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium-glucose co-transporter 2 inhibitor according to baseline BMI in the Dapagliflozin And Prevention of Adverse- outcomes in Heart Failure trial (DAPA-HF). METHODS AND RESULTS: Body mass index was examined using standard categories, i.e. underweight ($<$18.5 kg/m(2) ); normal weight (18.5-24.9 kg/m(2) ); overweight (25.0-29.9 kg/m(2) ); obesity class I (30.0-34.9 kg/m(2) ); obesity class II (35.0-39.9 kg/m(2) ); and obesity class III ($>$/=40 kg/m(2) ). The primary outcome in DAPA-HF was the composite of worsening heart failure or cardiovascular death. Overall, 1348 patients (28.4%) were under/normal- weight, 1722 (36.3%) overweight, 1013 (21.4%) obesity class I and 659 (13.9%) obesity class II/III. The unadjusted hazard ratio (95% confidence interval) for the primary outcome with obesity class 1, the lowest risk group, as reference was: under/normal-weight 1.41 (1.16-1.71), overweight 1.18 (0.97-1.42), obesity class II/III 1.37 (1.10-1.72). Patients with class I obesity were also at lowest risk of death. The effect of dapagliflozin on the primary outcome and other outcomes did not vary by baseline BMI, e.g. hazard ratio for primary outcome: under/normal-weight 0.74 (0.58-0.94), overweight 0.81 (0.65-1.02), obesity class I 0.68 (0.50-0.92), obesity class II/III 0.71 (0.51-1.00) (P-value for interaction = 0.79). The mean decrease in weight at 8 months with dapagliflozin was 0.9 (0.7-1.1) kg (P $<$ 0.001). CONCLUSION: We confirmed an ’obesity survival paradox’ in HFrEF. We showed that dapagliflozin was beneficial across the wide range of BMI studied. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT03036124.
|
|
| 4. |
- Johansson, Jonas, et al.
(författare)
-
Solar disinfection at low costs: an experimental approach towards up-scaled continuous flow systems
- 2022
-
Ingår i: H2open Journal. - : IWA Publishing. - 2616-6518. ; 5:1, s. 153-165
-
Tidskriftsartikel (refereegranskat)abstract
- SOlar DISinfection (SODIS) systems have been studied with the aim of maintaining pathogen removal efficiencies and low costs. Such systems are useful for quickly improving the situation of more than 700 million people worldwide that lack access to an improved water source. Currently, SODIS is mainly used with PET-bottles that are exposed to UV-A radiation for 6 h in the sun. Up-scaled continuous flow SODIS systems could instead provide a continuous source of drinking water, whereas the use of plastic tubes, easily available on local markets, ensures a low construction cost of the systems. Such tubes (PVC) were tested and the best option showed a UV-A transparency ratio of similar to 50%, to be compared with similar to 60% for PET-bottles. By using static batches in samples of this tube, the residence time was investigated and the results show that E. coli concentrations of 0 CFU/ml are reached within less than 4 h of exposure to solar radiation, starting from an initial concentration of 10(6) CFU/ml. It can be concluded that cheap, easily available plastic tubes can be used for treating contaminated water with the SODIS technique, which is promising for future investigations towards constructing continuous flow SODIS systems at low costs.
|
|
